Johnson & Johnson (JNJ): Today's Featured Drugs Loser

Johnson & Johnson ( JNJ) pushed the Drugs industry lower today making it today's featured Drugs loser. The industry as a whole closed the day down 1.8%. By the end of trading, Johnson & Johnson fell 60 cents (-0.9%) to $64.74 on average volume. Throughout the day, 10.2 million shares of Johnson & Johnson exchanged hands as compared to its average daily volume of 10.1 million shares. The stock ranged in price between $64.74-$65.29 after having opened the day at $65.19 as compared to the previous trading day's close of $65.34. Other company's within the Drugs industry that declined today were: Synergy Pharmaceuticals ( SGYP), down 20.9%, Alexza Pharmaceuticals ( ALXA), down 19.7%, Anika Therapeutics ( ANIK), down 17%, and Cadence Pharmaceuticals ( CADX), down 16.7%.

Johnson & Johnson engages in the research, development, manufacture, and sale of various products in the health care field worldwide. Johnson & Johnson has a market cap of $179.35 billion and is part of the health care sector. The company has a P/E ratio of 18.4, above the average drugs industry P/E ratio of 17.9 and above the S&P 500 P/E ratio of 17.7. Shares are down 0.4% year to date as of the close of trading on Thursday. Currently there are 12 analysts that rate Johnson & Johnson a buy, no analysts rate it a sell, and 11 rate it a hold.

TheStreet Ratings rates Johnson & Johnson as a buy. The company's strengths can be seen in multiple areas, such as its growth in earnings per share, expanding profit margins and increase in net income. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself.

On the positive front, Cormedix ( CRMD), up 16.7%, Opexa Therapeutics ( OPXA), up 15.1%, Aoxing Pharmaceutical Company ( AXN), up 13.9%, and Transition Therapeutics ( TTHI), up 10%, were all gainers within the drugs industry with Sequenom ( SQNM) being today's featured drugs industry winner.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).
null

If you liked this article you might like

60 Seconds: Own Dividend Stocks And Get Paid Even When The Market Tanks

60 Seconds: Own Dividend Stocks And Get Paid Even When The Market Tanks

Jim Cramer: You Have to Decide If You Want to Profit From This Moment

Jim Cramer: You Have to Decide If You Want to Profit From This Moment

Dow Drops Over 250 Points to End Six-Session Winning Streak

Dow Drops Over 250 Points to End Six-Session Winning Streak

Buy Stocks That Are Right for You: Cramer's 'Mad Money' Recap (Friday 2/16/18)

Buy Stocks That Are Right for You: Cramer's 'Mad Money' Recap (Friday 2/16/18)

Jim Cramer: These 4 Stocks Seem Attractive Right Here

Jim Cramer: These 4 Stocks Seem Attractive Right Here